Clinical course and features of thyroid oncocytic (Hurthle cell) cancer: Comparison with thyroid follicular cancer Curso clínico y características del cáncer oncocítico de tiroides (células de Hürthle): comparación con el carcinoma folicular de tiroides
Revista Espanola de Medicina Nuclear e Imagen Molecular, cilt.44, sa.6, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 6
- Basım Tarihi: 2025
- Doi Numarası: 10.1016/j.remn.2025.500158
- Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
- Anahtar Kelimeler: Oncocytic thyroid cancer, Follicular thyroid cancer, Recurrence, Predictor variable
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction and objectives Although oncocytic (Hurthle cell) carcinoma (OTC) resembles to follicular thyroid carcinoma (FTC), they are different tumours derived from thyroid follicular cells. OTC comprises 3-5% of all differentiated thyroid carcinomas and has more aggressive behaviour than FTC. Clinicians discuss about the treatment and prognosis of OTC. We evaluated its clinicopathological features and clinical course. Material and methods We examined and followed up 169 patients with OTC (126 minimally invasive, 43 widely invasive) and 837 patients with FTC (640 minimally invasive, 197 widely invasive). OTC and FTC were compared according to prognostic variables, recurrence rate (Rec) and outcome. The predictor factors impacting on recurrence in OTC were also determined. Results There were statistically significant differences between OTC and FTC in age, sex, capsule invasion (CI), tumor size (TS), total administered [131I]NaI dose (TID), stimulated thyroglobulin (sTg), Rec and stage ( P < .001, P = .032, P < .001, P < .001, P = .004, P = .026, P = .017, P = .044, respectively). Age, CI, extrathyroidal extension (ETE), TS, initial lymph node metastasis (ILNM), sTg and stage ( P = .01, P = .016, P < .001, P < .001, P < .001, P < .001, P < .001, respectively) were the predictors for recurrence in OTC. Metastasis incidence was 19.5% for OTC and 12% for FTC. The cause of death was cancer in 25 patients with FTC (2.8%) and 11 patients with OTC (6.5%). Conclusion The prognosis of minimally invasive OTC is quite favorable. However the prognosis of widely invasive OTC is unfavorable. RAI may be administered to these tumors, but it is in vain to insist on RAI after the first adjuvant therapy if it does not respond.